VC
EPRX

Vivo Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Vivo Capital’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.77M Hold
1,350,000
– – 0.81% 32
2025
Q4 		$10.2M Hold
1,350,000
– – 0.66% 34
2025
Q3 		$7.96M Buy
+1,350,000
New +$7.35M 0.64% 35

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vivo Capital's EPRX Position: Q1 2026 in Review

Vivo Capital held its Eupraxia Pharmaceuticals (EPRX) position steady in Q1 2026 at 1,350,000 shares worth $9.77M. The position accounts for 0.81% of the portfolio, ranked #32.

Vivo Capital first reported a position in EPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $10.2M in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Vivo Capital held 1,350,000 shares of Eupraxia Pharmaceuticals worth $9.77M as of Q1 2026.
  • Vivo Capital left its Eupraxia Pharmaceuticals share count unchanged in Q1 2026.
  • Eupraxia Pharmaceuticals made up 0.81% of Vivo Capital's portfolio in Q1 2026, its #32 holding.
  • Vivo Capital first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Vivo Capital's Eupraxia Pharmaceuticals position peaked at $10.2M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.